G Protein‐Coupled Receptors as Drug Targets (2005)

Preface. A Personal Foreword. List of Contributors. Abbreviations and Terminology. I: General Concepts. 1. Historical Background and Introduction. 2. The Nature of Constitutive Activity and Inverse Agonism. 2.1 Historical Perspective. 2.2 Theoretical Basis of Inverse Agonism: Relevance of Receptor Type. 2.3 The Interaction of Systems with Ligands. 2.4 Inverse Agonism as a Phenotypic Behavior. 2.5 Conclusion. 3. Molecular Mechanisms of GPCR Activation. 3.1 Introduction. 3.2 GPCR Structure and Ligand Recognition. 3.3 Conformational Changes in the GPCR Activation Process. 3.4 Conversion to the Active Receptor State Involves Release of Stabilizing Intramolecular Interactions. 3.5 Kinetics of Agonist Binding and Receptor Activation. 3.6 GPCR Activation in an Oligomeric Context. 4. Molecular and Cellular Determinants of GPCR Splice Variant Constitutive Activity. 4.1 Introduction. 4.2 Constitutive Activation of Second Messenger Production by C-Terminal Splice Variants of GPCRs. 4.3 Differential Constitutive Internalization of C-t GPCR Splice Variants. 4.4 Conclusion. 5. Naturally Occurring Constitutively Active Receptors: Physiological and Pharmacological Implications. 5.1 Introduction. 5.2 Wild-type Interspecies Homologues. 5.3 Wild-type Receptor Subtypes within a Given Species. 5.4 Wild-type Alternatively Spliced Receptors. 5.5 Polymorphisms in GPCRs. 5.6 GPCR Mutation-induced Disease. 5.7 Future Challenges. 6. The Impact of G Proteins on Constitutive GPCR Activity. 6.1 Introduction. 6.2 The Contribution of G proteins to Constitutive Activity. 6.3 GPCR-G Protein Fusion Proteins. 6.4 Conclusions. 7. (Patho)physiological and Therapeutic Relevance of Constitutive Activity and Inverse Agonism at G Protein-Coupled Receptors. 7.1 Introduction. 7.2 Physiological Relevance of Constitutive Activity of GPCRs. 7.3 Constitutive Activity of GPCRs and Pathophysiology of Disease. 7.4 Physiological Relevance of Inverse Agonists. 7.5 Inverse Agonists as Drugs. 7.6 Conclusions. 8. Methodological Approaches. 8.1 Introduction. 8.2 Analysis of Constitutive GPCR Activity in Membranes and Intact Cells. 8.3 Measurement of Constitutive Activity of GPCRs in Intact Cells. II: Constitutive Activity of Selected GPCR Systems. 9. Constitutive Activity of b-Adrenoceptors: Analysis in Membrane Systems. 9.1 Introduction. 9.2 Analysis of betaAR/Gs Protein Coupling in Membranes. 9.3 Development of the Concept that betaARs are Constitutively Active. 9.4 Probing Models of GPCR Activation with beta2ARwt and beta2ARCAM with Inverse Agonists. 9.5 Probing Models of GPCR Activation with beta2ARwt and beta2ARCAM and with Partial and Full Agonists. 9.6 Probing Models of GPCR Activation with beta2ARwt and Purine Nucleotides. 9.7 Constitutive Activity of the beta2AR Coupled to Various GALPHAs Proteins. 9.8 Probing Models of GPCR Activation with beta2AR Coupled to Various Classes of G proteins. 9.9 Comparison of the Constitutive Activities of the beta1AR and the beta2AR. 9.10 Conclusions. 10. Constitutive Activity of BETA-Adrenoceptors: Analysis by Physiological Methods. 10.1 Introduction. 10.2 Constitutive Activity and Inverse Agonism: Definition and Detection. 10.3 beta1-Adrenoceptors. 10.4 beta2-Adrenoceptors. 10.5 Homo- and Heterodimerization of beta1- and beta2ARs. 10.6 Conclusions. 11. Constitutive Activity at the alpha1-Adrenoceptors: Past and Future Implications. 11.1 Introduction. 11.2 Theoretical and Experimental Approaches for Study of Constitutive GPCR Activity. 11.3 Constitutively Activating Mutations of the alpha1AR Subtypes. 11.4 A Putative Model of Receptor Activation for the alpha1BAR. 11.5 Constitutive Activity of Wild-type alpha1ARs and Inverse Agonism. 11.6 Receptor Regulation and Constitutive Activity of the alpha1ARs. 11.7 Conclusions. 12. Constitutive Activity of Muscarinic Acetylcholine Receptors: Implications for Receptor Activation and Physiological Relevance. 12.1 Introduction. 12.2 Constitutive Activity - Native Systems. 12.3 Constitutive Activity - Recombinant Systems. 12.4 Constitutive Activation by G Proteins. 12.5 Structure-Function Analysis of Receptor Activation. 12.6 Structure-Function Model for Activation. 12.7 Conclusions. 13. Constitutively Active Histamine Receptors. 13.1 Introduction. 13.2 The Histamine Receptors. 13.3 Assay Systems for Detection of Constitutive Activity of Histamine Receptors. 13.4 Conclusions. 14. Constitutively Active Serotonin Receptors. 14.1 Introduction. 14.2 5-HT1A Receptor (5-HT1AR). 14.3 5-HT1B and 5-HT1D Receptors (5-HT1BR and 5-HT1DR). 14.4 5-HT2A Receptor (5-HT2AR). 14.5 5-HT2C Receptor (5-HT2CR). 14.6 Conclusion. 15. Virally Encoded Constitutively Active Chemokine Receptors. 15.1 Introduction. 15.2 The Human Cytomegalovirus-encoded Chemokine Receptor Homologue pUS28. 15.3 The Human Kaposi's Sarcoma Virus-encoded Chemokine Receptor KSHV-GPCR. 15.4 Conclusions. Index.